Metabolomes of mitochondrial diseases and inclusion body myositis patients: treatment targets and biomarkers
Jana Buzková(University of Helsinki), Anu Suomalainen(University of Helsinki), Hannele Yki‐Järvinen(University of Helsinki), Anna H. Hakonen(University of Helsinki), Topi Hovinen(University of Helsinki), Joni Nikkanen(University of Helsinki), Kirsi H. Pietiläinen(University of Helsinki), Tuula Lönnqvist(University of Helsinki), Ksenia Sevastianova(University of Helsinki), Vidya Velagapudi(University of Helsinki), Sofia Ahola(Institute for Molecular Medicine Finland), Christopher J. Carroll(St George's, University of London)
Cited by 75
Related Papers
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
Mitochondrial diseases
|Nature Reviews Disease Primers|2016|1.5k
Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors
|Gastroenterology|2009|804
An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans
|Cell Metabolism|2018|482
FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study
|The Lancet Neurology|2011|420